Explore GallantU: free, RACE-approved CE for veterinary professionals

News Releases

Gallant Achieves FDA “Technical Section Complete” for Reasonable Expectation of Effectiveness, Advancing First Ready-to-Use Stem Cell Therapy

Gallant Debuts GallantU: A Comprehensive CE Platform Preparing Veterinary Professionals for the Regenerative Medicine Era

Announcement text on blue background: "Gallant Closes $18 Million Series B"

Gallant Closes $18 Million Series B to Bring Ready-to-Use Stem Cell Therapies for Pets to Market

Rebecca Windsor

Gallant Names Dr. Rebecca Windsor Director of Veterinary Affairs as Company Advances Its Off-the-Shelf Stem Cell Therapy for Cats

Illustration of stem cell therapy study targeting cats and dogs

Gallant Therapeutics Raises Over $15 Million in Series A Funding to Advance Pipeline of “Off-the-Shelf” Stem Cell Therapies for Pets

Illustration of a cat at veterinarian exam

Gallant Therapeutics Announces Launch of JEDI Pivotal Study for First Allogeneic Stem Cell Therapy Targeting Feline Chronic Gingivostomatitis

Four pugs

Ethos Discovery and Gallant Therapeutics Collaborate on Study Evaluating Gallant’s Stem Cell Therapy in Pugs with Necrotizing Meningoencephalitis (NME), also referred to as Pug Dog Encephalitis (PDE)

Gallant is redefining veterinary medicine with ready-to-use stem cell therapies that reduce inflammation, restore function, and fit seamlessly into everyday practice.

10865 Road to the Cure, Ste 101
San Diego, CA 92121
+1-855-442-5526
info@gallant.com
Get Help

Subscribe for thoughtful updates on clinical trials, product development, and the future of regenerative pet care.

© 2019-2025 Gallant. All Rights Reserved.
Terms & Conditions. Privacy Policy. Copyright & Cookies.